Skip to main content
. 2010 Sep;21(9):1587–1596. doi: 10.1681/ASN.2009111109

Figure 3.

Figure 3.

Low occurrence of death or graft loss in belatacept-treated patients over time. The Kaplan-Meier plot is for all randomly assigned and transplant recipients in the ITT population without cancer over 60 months. Meddra 11.0 was used for skin and organ cancer; Meddra 10.0 was used for PTLD. Patients with events of cancer including skin, organ cancer, or PTLD were excluded.